Atlas Trials

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Clinical trial NCT06213311 · RECRUITING

Trial details

NCT number
NCT06213311
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
B Cell Lymphoma
Start date
2024-05-07
Primary completion
2027-07-31
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.